Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 27,482 | 24,215 | 20,254 | 24,565 | 25,204 |
| Cost of Goods | 3,278 | 3,550 | 2,330 | 2,471 | 2,453 |
| Gross Profit | 24,204 | 20,665 | 17,924 | 22,094 | 22,751 |
| Operating Expenses | 51,868 | 62,663 | 55,168 | 50,223 | 40,749 |
| Operating Income | -27,386 | -41,448 | -36,914 | -27,658 | -17,545 |
| Interest Expense | 3,373 | 4,132 | 4,068 | 3,892 | 2,721 |
| Other Income | -3,642 | -3,345 | -2,469 | -3,313 | -3,316 |
| Pre-tax Income | -34,401 | -48,925 | -43,451 | -34,863 | -23,582 |
| Income Tax | -1,054 | 1,015 | 392 | 2,649 | 91 |
| Net Income Continuous | -33,347 | -49,940 | -43,843 | -37,512 | -23,673 |
| Net Income | $-33,347 | $-49,940 | $-43,843 | $-37,512 | $-23,673 |
| EPS Basic Total Ops | -0.69 | -1.05 | -0.92 | -0.76 | -0.51 |
| EPS Basic Continuous Ops | -0.69 | -1.05 | -0.92 | -0.76 | -0.51 |
| EPS Diluted Total Ops | -0.69 | -1.05 | -0.92 | -0.76 | -0.51 |
| EPS Diluted Continuous Ops | -0.69 | -1.05 | -0.92 | -0.76 | -0.51 |
| EPS Diluted Before Non-Recurring Items | -0.69 | -1.05 | -0.92 | -0.80 | -0.55 |
| EBITDA(a) | $-27,466 | $-42,234 | $-37,616 | $-28,926 | $-18,551 |